MTN-028 Study Product Considerations Overview
M
T
N
-
0
2
8
S
t
u
d
y
P
r
o
d
u
c
t
C
o
n
s
i
d
e
r
a
t
i
o
n
s
Cindy Jacobson
Lindsay Kramzer
Microbicide Trials Network
Overview
Prescription Completion
Intravaginal Ring Supply and Labels
Chain of Custody
Intravaginal Ring Request Slip Completion
Used
versus
Unused
Intravaginal Ring
Return Processes
Study Product Complaints
Reference Materials
MTN-028 Protocol, Version 1.0
Section 6
MTN-028 SSP
Section 7
Site-Specific Clinic Study Product
Accountability and Destruction SOP (non-
pharmacy) for MTN-028
Study Product Regimen
One IVR will be inserted into the
participant’s vagina at:
Enrollment Visit (Visit 2)
E
a
c
h
p
a
r
t
i
c
i
p
a
n
t
i
s
a
n
t
i
c
i
p
a
t
e
d
t
o
u
s
e
o
n
e
I
V
R
f
o
r
a
d
u
r
a
t
i
o
n
o
f
a
p
p
r
o
x
i
m
a
t
e
l
y
2
8
d
a
y
s
Study Visit Schedule
Study Randomization
Participants will be randomized in a 2:1 ratio
Enrollment Visit
R
a
n
d
o
m
i
z
a
t
i
o
n
t
o
s
t
u
d
y
p
r
o
d
u
c
t
o
c
c
u
r
s
a
t
t
h
e
E
n
r
o
l
l
m
e
n
t
V
i
s
i
t
Participant randomization will be conducted via
the Frontier Science & Technology Research
Foundation, Inc. (FSTRF) web-based system
O
n
c
e
a
c
l
i
n
i
c
s
t
a
f
f
m
e
m
b
e
r
s
u
b
m
i
t
s
r
e
q
u
i
r
e
d
p
a
r
t
i
c
i
p
a
n
t
i
n
f
o
f
o
r
e
n
r
o
l
l
m
e
n
t
/
r
a
n
d
o
m
i
z
a
t
i
o
n
,
d
e
s
i
g
n
a
t
e
d
c
l
i
n
i
c
a
n
d
p
h
a
r
m
a
c
y
s
t
a
f
f
w
i
l
l
r
e
c
e
i
v
e
F
S
T
R
F
r
a
n
d
o
m
i
z
a
t
i
o
n
c
o
n
f
i
r
m
a
t
i
o
n
n
o
t
i
c
e
v
i
a
e
m
a
i
l
Enrollment Visit
P
r
e
s
c
r
i
p
t
i
o
n
w
i
l
l
b
e
c
o
m
p
l
e
t
e
d
a
t
E
n
r
o
l
l
m
e
n
t
V
i
s
i
t
2 part no carbon required (NCR) paper document.
The top white is the original (pharmacy).
The bottom yellow is the copy (clinic).
Prescriptions are provided to clinic staff by MTN
LOC Pharmacy.
Enrollment Visit
1.
R
a
n
d
o
m
i
z
e
p
a
r
t
i
c
i
p
a
n
t
v
i
a
t
h
e
o
n
l
i
n
e
F
S
T
R
F
s
y
s
t
e
m
.
2.
P
r
i
n
t
p
a
r
t
i
c
i
p
a
n
t
’
s
r
a
n
d
o
m
i
z
a
t
i
o
n
c
o
n
f
i
r
m
a
t
i
o
n
n
o
t
i
c
e
a
n
d
s
a
v
e
.
3.
C
o
m
p
l
e
t
e
t
h
e
p
a
r
t
i
c
i
p
a
n
t
’
s
p
r
e
s
c
r
i
p
t
i
o
n
.
4.
F
a
x
t
h
e
p
r
e
s
c
r
i
p
t
i
o
n
(
t
o
p
w
h
i
t
e
)
a
n
d
r
a
n
d
o
m
i
z
a
t
i
o
n
c
o
n
f
i
r
m
a
t
i
o
n
n
o
t
i
c
e
t
o
t
h
e
p
h
a
r
m
a
c
y
.
5.
O
n
c
e
a
w
e
e
k
,
s
e
n
d
a
l
l
o
r
i
g
i
n
a
l
p
r
e
s
c
r
i
p
t
i
o
n
s
(
t
o
p
w
h
i
t
e
)
a
n
d
c
o
r
r
e
s
p
o
n
d
i
n
g
c
o
p
i
e
s
o
f
t
h
e
r
a
n
d
o
m
i
z
a
t
i
o
n
c
o
n
f
i
r
m
a
t
i
o
n
n
o
t
i
c
e
s
t
o
t
h
e
p
h
a
r
m
a
c
y
.
MTN-028 Prescription
T
o
B
e
C
o
m
p
l
e
t
e
d
b
y
C
l
i
n
i
c
S
t
a
f
f
:
CRS Name, CRS ID, CRS Location,
Randomization #, Participant ID (PTID)
Indication of participant provision of informed
consent/Clinic Staff Initials
Authorized Prescriber Name (FDA 1572),
Signature, and Date
Clinic Staff Initials and Date (below Clinic Staff
Instructions)
MTN-028 Prescription
Double check the accuracy of all entries
Errors may be corrected in blue or black ink by
putting a line through and initialing
Retain the yellow copy for the participant study
notebook in the clinic
F
a
x
a
n
d
D
e
l
i
v
e
r
w
h
i
t
e
c
o
p
y
t
o
p
h
a
r
m
a
c
y
MTN-028 Prescription
The pharmacist will review the prescription.
If an error is noted, the white and yellow copies
must be individually corrected by an authorized
prescriber with identical information on both
copies.
If no problems are noted, the pharmacist will
dispense the study product.
MTN-028 Study Product – Intravaginal Ring
Overall, like NuvaRing
•
Smooth, flexible
•
Outer diameter: 54mm
•
Cross sectional diameter: 4mm
H
O
W
E
V
E
R
,
M
T
N
-
0
2
8
I
V
R
S
a
r
e
•
W
h
i
t
e
t
o
o
f
f
-
w
h
i
t
e
,
o
p
a
q
u
e
•
O
r
i
g
i
n
a
l
D
o
s
e
>
L
o
w
D
o
s
e
MTN-028 Study Product – Intravaginal Ring
Vicriviroc (VCV; MK-4176)
CCR5 Inhibitor
MK-2048
Integrase Inhibitor
MK-2048A
Term for the combination IVR
Vicriviroc (VCV; MK-4176)
VCV (MK-4176) is a CYP3A4 substrate
Extensively metabolized by CYP3A4
Participants must be counseled to avoid certain
scheduled/routine CYP3A4 inhibitors and inducers via
any route of administration
Refer to SSP Section 7.7
Appendices 7-3 and 7-4
Note: Single dose oral fluconazole is permitted.
If you have further questions, please contact the MTN-
028 PSRT (
mtn028psrt@mtnstopshiv.org
).
MTN-028 Study Product – Intravaginal Ring
IVRs are individually wrapped (overwrap pouch) and
labeled
IVRs consist of a closed-ring fiber having two layers:
core and skin.
Core layer contains VCV
Skin layer contains MK-2048
Both drugs are dispersed in ethylene vinyl acetate (EVA)
copolymer
IVR is designed to provide sustained release of drug
over 28-day period
M
T
N
-
0
2
8
I
V
R
P
o
u
c
h
L
a
b
e
l
PoR will indicate PTID
and dispensation
date/time prior to
dispensing IVR
M
T
N
-
0
2
8
R
e
t
u
r
n
e
d
U
s
e
d
I
V
R
L
a
b
e
l
(
o
n
w
h
i
t
e
b
a
g
)
PoR to indicate
Clinic Staff to indicate
Chain Of Custody
The study product must be tracked with
documentation, from the pharmacy to the
participant and all steps in between.
Study product (one IVR) may be prepared and
dispensed by the pharmacist based on either
original documents or faxed copies.
Chain Of Custody
Study Product is dispensed by pharmacy staff to:
Clinic staff who will then deliver the IVR to the
participant
T
o
c
o
u
r
i
e
r
/
r
u
n
n
e
r
w
h
o
d
e
l
i
v
e
r
s
t
h
e
I
V
R
t
o
c
l
i
n
i
c
s
t
a
f
f
w
h
o
w
i
l
l
t
h
e
n
p
r
o
v
i
d
e
t
h
e
I
V
R
t
o
t
h
e
p
a
r
t
i
c
i
p
a
n
t
Depends on pharmacy site-specific Chain of Custody
SOP
C
h
a
i
n
o
f
C
u
s
t
o
d
y
f
r
o
m
p
h
a
r
m
a
c
y
s
t
a
f
f
t
o
c
o
u
r
i
e
r
i
s
d
o
c
u
m
e
n
t
e
d
o
n
t
h
e
M
T
N
-
0
2
8
D
e
l
i
v
e
r
y
D
o
c
u
m
e
n
t
a
t
i
o
n
F
o
r
m
a
t
t
i
m
e
o
f
I
V
R
d
i
s
p
e
n
s
a
t
i
o
n
M
T
N
-
0
2
8
D
e
l
i
v
e
r
y
D
o
c
u
m
e
n
t
a
t
i
o
n
F
o
r
m
Chain of Custody
C
l
i
n
i
c
S
t
a
f
f
R
e
s
p
o
n
s
i
b
i
l
i
t
i
e
s
Control access to the IVRs in clinic staff
custody
Clinic staff must document delivery of the
IVR to the designated participant on the
Participant-Specific Clinic Study Product
Accountability Log
Chain of Custody
C
l
i
n
i
c
S
t
a
f
f
R
e
s
p
o
n
s
i
b
i
l
i
t
i
e
s
I
f
a
n
I
V
R
d
i
s
p
e
n
s
e
d
f
o
r
a
p
a
r
t
i
c
i
p
a
n
t
i
s
n
o
t
p
r
o
v
i
d
e
d
t
o
t
h
e
p
a
r
t
i
c
i
p
a
n
t
,
c
l
i
n
i
c
s
t
a
f
f
m
u
s
t
d
o
c
u
m
e
n
t
t
h
i
s
i
n
t
h
e
p
a
r
t
i
c
i
p
a
n
t
'
s
s
t
u
d
y
c
h
a
r
t
a
n
d
r
e
t
u
r
n
t
h
e
u
n
u
s
e
d
I
V
R
t
o
t
h
e
p
h
a
r
m
a
c
y
a
s
s
o
o
n
a
s
p
a
r
t
i
c
i
p
a
n
t
’
s
v
i
s
i
t
i
s
c
o
m
p
l
e
t
e
d
.
Study Visit Schedule
It is anticipated that each participant will only need
one IVR
for the duration of study participation.
Dispensing IVR during Follow-Up
Scheduled follow-up visits, as needed
Interim visits, as needed
C
l
i
n
i
c
S
t
a
f
f
w
i
l
l
i
n
d
i
c
a
t
e
R
E
-
S
U
P
P
L
Y
o
n
a
n
M
T
N
-
0
2
7
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
R
e
q
u
e
s
t
S
l
i
p
Request Slip is a 2 part no carbon required (NCR)
paper document. The top white is the original
(pharmacy) and the bottom is yellow (clinic).
Request Slips are provided to clinic staff by
MTN LOC Pharmacy.
M
T
N
-
0
2
8
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
R
e
q
u
e
s
t
S
l
i
p
IVR Request Slip Completion
This slip can be completed by any authorized clinic
staff
except
in the case of indicating “RESUME”
Only authorized prescribers can indicate “RESUME”
Double check the accuracy of all entries
Errors may be corrected in blue or black ink by
putting a line through and initialing
Retain the yellow copy for the participant study
notebook in the clinic
F
a
x
a
n
d
t
h
e
n
d
e
l
i
v
e
r
(
b
a
t
c
h
e
d
)
w
h
i
t
e
c
o
p
y
t
o
p
h
a
r
m
a
c
y
Once the white and yellow copies are separated
errors must be corrected on each sheet separately
IVR Request Slip Completion
R
E
-
S
U
P
P
L
Y
Used by clinic staff to communicate to
pharmacist the study product quantity to be
re-supplied to each participant at follow-up
visits (scheduled and unscheduled/interim
visits)
One IVR
Never more than one IVR
IVR RE-SUPPLY
At minimum, the following procedures must be
conducted in order to dispense study product
at follow-up:
AE assessment and clinical management
Protocol Section 8
Pregnancy test and/or HIV test, if indicated/IoR
discretion
Must be negative prior to IVR re-supply
Collection of used/unused IVR, if available
Adherence Counseling/Vaginal Ring Use
Instructions, as needed
M
T
N
-
0
2
8
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
R
e
q
u
e
s
t
S
l
i
p
IVR Request Slip Completion
H
O
L
D
Used by clinic staff to
communicate to pharmacist that
the participant has a temporary
IVR hold due to a clinical/safety
reason(s)
Record reason for hold
IVR Request Slip Completion
R
E
S
U
M
E
Once a product hold is in effect, the
pharmacist will not dispense any study
product to that participant until a subsequent
request slip is received and “RESUME” is
marked on that request slip
One IVR
Only an authorized prescriber indicated on
the FDA 1572 form can initiate a VR resume
IVR Request Slip Completion
P
A
R
T
I
C
I
P
A
N
T
D
E
C
L
I
N
E
If a participant decides that she does not
want to use the IVR, then the box for
“PARTICIPANT DECLINE” is marked
This is not a clinical hold and does not
require a “RESUME’
When the participant wants to continue
product, the clinic staff will complete a new
request slip for RE-SUPPLY
One IVR
IVR Request Slip Completion
P
E
R
M
A
N
E
N
T
D
I
S
C
O
N
T
I
N
U
A
T
I
O
N
If study clinician determines that a participant
should permanently stop IVR use due to
safety reason(s), then the box for
“PERMANENT DISCONTINUATION” is
marked
Indicate reason for permanent discontinuation
Future IVR request slips will no longer be
completed at the participant’s remaining study
visits
IVR Request Slip Completion
P
R
O
D
U
C
T
U
S
E
P
E
R
I
O
D
C
O
M
P
L
E
T
E
D
Used by clinic staff to communicate to the
pharmacy when the participant has
completed
or
withdrawn
from the study
IVR Request Slip
A
t
m
i
n
i
m
u
m
,
t
h
e
R
e
q
u
e
s
t
S
l
i
p
s
h
o
u
l
d
b
e
u
s
e
d
f
o
r
:
One scheduled
Product Use Period
Completed
Day 28, Visit 9
Retrieval of IVR
Review protocol section 6.4.4 for
guidelines regarding ring retrieval
following discontinuation, hold and Final
Clinic Visit
Document all efforts to retrieve study
product in chart notes, if study product is
not returned by the participant
Retrieval of IVR
If not retrieved within timeframe stated above, the MTN-028
PSRT must be informed. All attempts to retrieve product
should be documented.
Retrieval of IVR
It is not necessary to retrieve IVR from participant for whom
IVR use is being temporarily held for less than 7 days.
However, IVR can be retrieved to protect participant’s safety
(IoR discretion).
All IVRs remaining in the participants possession should be
retrieved at/by Visit 9/Day 28. If the participant does not bring
the ring back at this visit, clinic staff need to arrange to retrieve
the ring within 2 business days
.
If the IVR is not retrieved
within that timeframe, the MTN-028 PSRT must be informed.
Retrieval of IVR
IVR retrieval may occur by the participant
returning the IVR to study staff within the
specified timeframe or attempts should be
made by study staff to contact the
participant to retrieve IVR as soon as
possible
Always document retrieval efforts
U
S
E
D
V
a
g
i
n
a
l
R
i
n
g
R
e
t
u
r
n
/
D
e
s
t
r
u
c
t
i
o
n
Follow your Site-Specific Clinic Study
Product Accountability and Destruction
SOP (non-pharmacy) for MTN-028
Participant-Specific Clinic Study Product
Accountability Log
Clinic Study Product Destruction Log
Expect this to be very rare
U
n
u
s
e
d
V
a
g
i
n
a
l
R
i
n
g
R
e
t
u
r
n
ONLY unused study product should be returned to the
pharmacy
NO USED IVRs should be returned to the pharmacy
Used IVRs will be forwarded to lab or for destruction
Unused IVR is returned to the pharmacy by:
Clinic staff member or courier/runner
Depends on pharmacy site-specific Chain of Custody SOP
D
o
c
u
m
e
n
t
e
d
o
n
R
e
c
o
r
d
o
f
R
e
t
u
r
n
o
f
S
i
t
e
-
S
p
e
c
i
f
i
c
U
n
u
s
e
d
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
s
This record is stored in the pharmacy
I
f
r
e
t
u
r
n
i
n
g
u
n
u
s
e
d
I
V
R
b
e
c
a
u
s
e
d
a
m
a
g
e
d
o
r
c
o
n
t
a
m
i
n
a
t
e
d
,
r
e
c
o
r
d
t
h
e
d
e
t
a
i
l
s
o
n
t
h
e
r
e
c
o
r
d
The pharmacy will document and quarantine
any returned unused IVRs
Chain Of Custody
M
T
N
-
0
2
8
R
e
c
o
r
d
o
f
R
e
t
u
r
n
o
f
U
n
u
s
e
d
S
i
t
e
-
S
p
e
c
i
f
i
c
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
s
Study Product Complaints
Study product problem may be noted by pharmacy,
clinic, and/or participant.
May concern dosage form (IVR), packaging (overwrap),
or other aspect.
Clinic staff will make thorough record of clinic staff
or participant complaint.
Clinic staff member will email complaint to
pharmacy.
Date of observed issue, date issue was reported, date
IVR was dispensed, did adverse event occur, nature of
issue, picture (if possible and applicable), any other
necessary details
Study Product Complaints
Pharmacy staff will email all study product
complaints to MTN LOC Pharmacy.
MTN LOC Pharmacy will forward complaints to
Merck to be submitted to the Merck Internal
Complaint Process.
If the complaint is concerning an unused IVR,
then the unused IVR should be held in quarantine
in the pharmacy.
If the complaint is concerning a used IVR, then the
clinic staff should process the IVR per standard
operating procedures for used IVRs.
Supplies Provided
MTN LOC Pharmacist will ship
(
No order necessary)
T
o
P
h
a
r
m
a
c
y
:
3
0
L
a
b
e
l
e
d
U
s
e
d
I
V
R
R
e
t
u
r
n
B
a
g
s
(
w
h
i
t
e
)
3
5
P
a
r
t
i
c
i
p
a
n
t
-
S
p
e
c
i
f
i
c
P
h
a
r
m
a
c
y
D
i
s
p
e
n
s
i
n
g
R
e
c
o
r
d
s
T
o
C
l
i
n
i
c
:
3
5
P
r
e
s
c
r
i
p
t
i
o
n
s
5
0
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
R
e
q
u
e
s
t
S
l
i
p
s
1
C
a
s
e
o
f
M
a
l
e
C
o
n
d
o
m
s
5
S
a
m
p
l
e
I
n
t
r
a
v
a
g
i
n
a
l
R
i
n
g
s
(
D
e
m
o
n
s
t
r
a
t
i
o
n
O
N
L
Y
)
Contact Information
If you have any questions, please do not
hesitate to contact us:
Cindy Jacobson
(412) 641-8913
cjacobson@upmc.edu
Lindsay Kramzer
(412) 641-3865
fergusonlm@upmc.edu
T
h
a
n
k
Y
o
u
!
The MTN-028 study focuses on product considerations for intravaginal rings in microbicide trials. It covers prescription completion, supply chain management, ring insertion process, return procedures, and handling of product complaints. The study regimen involves a 28-day duration per participant, with randomization into low or original dose arms. Enrollment procedures include online randomization via FSTRF system, prescription completion, and communication between clinic staff and pharmacy. Reference materials and study visit schedules provide detailed guidelines for study conduct.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
MTN-028 Study Product Considerations Cindy Jacobson Lindsay Kramzer Microbicide Trials Network
Overview Prescription Completion Intravaginal Ring Supply and Labels Chain of Custody Intravaginal Ring Request Slip Completion Used versus Unused Intravaginal Ring Return Processes Study Product Complaints
Reference Materials MTN-028 Protocol, Version 1.0 Section 6 MTN-028 SSP Section 7 Site-Specific Clinic Study Product Accountability and Destruction SOP (non- pharmacy) for MTN-028
Study Product Regimen One IVR will be inserted into the participant s vagina at: Enrollment Visit (Visit 2) Each participant is anticipated to use one IVR for a duration of approximately 28 days
Study Randomization Participants will be randomized in a 2:1 ratio N 12 Low Dose MK-2048A IVR: VCV (MK-4176) 91mg + MK-2048 10mg 6 Original Dose MK-2048A IVR: VCV (MK-4176) 182mg + MK-2048 30mg Arm
Enrollment Visit Randomization to study product occurs at the Enrollment Visit Participant randomization will be conducted via the Frontier Science & Technology Research Foundation, Inc. (FSTRF) web-based system Once a clinic staff member submits required participant info for enrollment/randomization, designated clinic and pharmacy staff will receive FSTRF randomization confirmation notice via email
Enrollment Visit Prescription will be completed at Enrollment Visit 2 part no carbon required (NCR) paper document. The top white is the original (pharmacy). The bottom yellow is the copy (clinic). Prescriptions are provided to clinic staff by MTN LOC Pharmacy.
Enrollment Visit 1. Randomize participant via the online FSTRF system. 2. Print participant s randomization confirmation notice and save. 3. Complete the participant s prescription. 4. Fax the prescription (top white) and randomization confirmation notice to the pharmacy. 5. Once a week, send all original prescriptions (top white) and corresponding copies of the randomization confirmation notices to the pharmacy.
MTN-028 Prescription To Be Completed by Clinic Staff: CRS Name, CRS ID, CRS Location, Randomization #, Participant ID (PTID) Indication of participant provision of informed consent/Clinic Staff Initials Authorized Prescriber Name (FDA 1572), Signature, and Date Clinic Staff Initials and Date (below Clinic Staff Instructions)
MTN-028 Prescription Double check the accuracy of all entries Errors may be corrected in blue or black ink by putting a line through and initialing Retain the yellow copy for the participant study notebook in the clinic Fax and Deliver white copy to pharmacy
MTN-028 Prescription The pharmacist will review the prescription. If an error is noted, the white and yellow copies must be individually corrected by an authorized prescriber with identical information on both copies. If no problems are noted, the pharmacist will dispense the study product.
MTN-028 Study Product Intravaginal Ring Study Product Two IVRs: Low Dose MK-2048A IVR: VCV (MK-4176) 91mg + MK-2048 10mg Original Dose MK-2048A IVR: VCV (MK-4176) 182mg + MK-2048 30mg Overall, like NuvaRing Smooth, flexible Outer diameter: 54mm Cross sectional diameter: 4mm HOWEVER, MTN-028 IVRS are White to off-white, opaque Original Dose > Low Dose
MTN-028 Study Product Intravaginal Ring Vicriviroc (VCV; MK-4176) CCR5 Inhibitor MK-2048 Integrase Inhibitor MK-2048A Term for the combination IVR
Vicriviroc (VCV; MK-4176) VCV (MK-4176) is a CYP3A4 substrate Extensively metabolized by CYP3A4 Participants must be counseled to avoid certain scheduled/routine CYP3A4 inhibitors and inducers via any route of administration Refer to SSP Section 7.7 Appendices 7-3 and 7-4 Note: Single dose oral fluconazole is permitted. If you have further questions, please contact the MTN- 028 PSRT (mtn028psrt@mtnstopshiv.org).
MTN-028 Study Product Intravaginal Ring IVRs are individually wrapped (overwrap pouch) and labeled IVRs consist of a closed-ring fiber having two layers: core and skin. Core layer contains VCV Skin layer contains MK-2048 Both drugs are dispersed in ethylene vinyl acetate (EVA) copolymer IVR is designed to provide sustained release of drug over 28-day period
MTN-028 IVR Pouch Label PoR will indicate PTID and dispensation date/time prior to dispensing IVR
MTN-028 Returned Used IVR Label (on white bag) PoR to indicate Clinic Staff to indicate
Chain Of Custody The study product must be tracked with documentation, from the pharmacy to the participant and all steps in between. Study product (one IVR) may be prepared and dispensed by the pharmacist based on either original documents or faxed copies.
Chain Of Custody Study Product is dispensed by pharmacy staff to: Clinic staff who will then deliver the IVR to the participant To courier/runner who delivers the IVR to clinic staff who will then provide the IVR to the participant Depends on pharmacy site-specific Chain of Custody SOP Chain of Custody from pharmacy staff to courier is documented on the MTN-028 Delivery Documentation Form at time of IVR dispensation
Chain of Custody Clinic Staff Responsibilities Control access to the IVRs in clinic staff custody Clinic staff must document delivery of the IVR to the designated participant on the Participant-Specific Clinic Study Product Accountability Log
Chain of Custody Clinic Staff Responsibilities If an IVR dispensed for a participant is not provided to the participant, clinic staff must document this in the participant's study chart and return the unused IVR to the pharmacy as soon as participant s visit is completed.
Study Visit Schedule It is anticipated that each participant will only need one IVR for the duration of study participation.
Dispensing IVR during Follow-Up Scheduled follow-up visits, as needed Interim visits, as needed Clinic Staff will indicate RE-SUPPLY on an MTN-027 Intravaginal Ring Request Slip Request Slip is a 2 part no carbon required (NCR) paper document. The top white is the original (pharmacy) and the bottom is yellow (clinic). Request Slips are provided to clinic staff by MTN LOC Pharmacy.
IVR Request Slip Completion This slip can be completed by any authorized clinic staff except in the case of indicating RESUME Only authorized prescribers can indicate RESUME Double check the accuracy of all entries Errors may be corrected in blue or black ink by putting a line through and initialing Retain the yellow copy for the participant study notebook in the clinic Fax and then deliver (batched) white copy to pharmacy Once the white and yellow copies are separated errors must be corrected on each sheet separately
IVR Request Slip Completion RE-SUPPLY Used by clinic staff to communicate to pharmacist the study product quantity to be re-supplied to each participant at follow-up visits (scheduled and unscheduled/interim visits) One IVR Never more than one IVR
IVR RE-SUPPLY At minimum, the following procedures must be conducted in order to dispense study product at follow-up: AE assessment and clinical management Protocol Section 8 Pregnancy test and/or HIV test, if indicated/IoR discretion Must be negative prior to IVR re-supply Collection of used/unused IVR, if available Adherence Counseling/Vaginal Ring Use Instructions, as needed
IVR Request Slip Completion HOLD Used by clinic staff to communicate to pharmacist that the participant has a temporary IVR hold due to a clinical/safety reason(s) Record reason for hold
IVR Request Slip Completion RESUME Once a product hold is in effect, the pharmacist will not dispense any study product to that participant until a subsequent request slip is received and RESUME is marked on that request slip One IVR Only an authorized prescriber indicated on the FDA 1572 form can initiate a VR resume
IVR Request Slip Completion PARTICIPANT DECLINE If a participant decides that she does not want to use the IVR, then the box for PARTICIPANT DECLINE is marked This is not a clinical hold and does not require a RESUME When the participant wants to continue product, the clinic staff will complete a new request slip for RE-SUPPLY One IVR
IVR Request Slip Completion PERMANENT DISCONTINUATION If study clinician determines that a participant should permanently stop IVR use due to safety reason(s), then the box for PERMANENT DISCONTINUATION is marked Indicate reason for permanent discontinuation Future IVR request slips will no longer be completed at the participant s remaining study visits
IVR Request Slip Completion PRODUCT USE PERIOD COMPLETED Used by clinic staff to communicate to the pharmacy when the participant has completed or withdrawn from the study
IVR Request Slip At minimum, the Request Slip should be used for: One scheduled Product Use Period Completed Day 28, Visit 9
Retrieval of IVR Review protocol section 6.4.4 for guidelines regarding ring retrieval following discontinuation, hold and Final Clinic Visit Document all efforts to retrieve study product in chart notes, if study product is not returned by the participant
Retrieval of IVR If not retrieved within timeframe stated above, the MTN-028 PSRT must be informed. All attempts to retrieve product should be documented.
Retrieval of IVR It is not necessary to retrieve IVR from participant for whom IVR use is being temporarily held for less than 7 days. However, IVR can be retrieved to protect participant s safety (IoR discretion). All IVRs remaining in the participants possession should be retrieved at/by Visit 9/Day 28. If the participant does not bring the ring back at this visit, clinic staff need to arrange to retrieve the ring within 2 business days. If the IVR is not retrieved within that timeframe, the MTN-028 PSRT must be informed.
Retrieval of IVR IVR retrieval may occur by the participant returning the IVR to study staff within the specified timeframe or attempts should be made by study staff to contact the participant to retrieve IVR as soon as possible Always document retrieval efforts
USED Vaginal Ring Return/Destruction Follow your Site-Specific Clinic Study Product Accountability and Destruction SOP (non-pharmacy) for MTN-028 Participant-Specific Clinic Study Product Accountability Log Clinic Study Product Destruction Log Expect this to be very rare
Unused Vaginal Ring Return ONLY unused study product should be returned to the pharmacy NO USED IVRs should be returned to the pharmacy Used IVRs will be forwarded to lab or for destruction Unused IVR is returned to the pharmacy by: Clinic staff member or courier/runner Depends on pharmacy site-specific Chain of Custody SOP Documented on Record of Return of Site-Specific Unused Intravaginal Rings This record is stored in the pharmacy
Chain Of Custody If returning unused IVR because damaged or contaminated, record the details on the record The pharmacy will document and quarantine any returned unused IVRs
MTN-028 Record of Return of Unused Site-Specific Intravaginal Rings
Study Product Complaints Study product problem may be noted by pharmacy, clinic, and/or participant. May concern dosage form (IVR), packaging (overwrap), or other aspect. Clinic staff will make thorough record of clinic staff or participant complaint. Clinic staff member will email complaint to pharmacy. Date of observed issue, date issue was reported, date IVR was dispensed, did adverse event occur, nature of issue, picture (if possible and applicable), any other necessary details
Study Product Complaints Pharmacy staff will email all study product complaints to MTN LOC Pharmacy. MTN LOC Pharmacy will forward complaints to Merck to be submitted to the Merck Internal Complaint Process. If the complaint is concerning an unused IVR, then the unused IVR should be held in quarantine in the pharmacy. If the complaint is concerning a used IVR, then the clinic staff should process the IVR per standard operating procedures for used IVRs.
